Resonant Capital Advisors LLC Increases Position in Danaher Co. (NYSE:DHR)

Resonant Capital Advisors LLC lifted its stake in shares of Danaher Co. (NYSE:DHR) by 4.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,720 shares of the conglomerate’s stock after purchasing an additional 575 shares during the period. Resonant Capital Advisors LLC’s holdings in Danaher were worth $3,432,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC increased its position in shares of Danaher by 20.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after purchasing an additional 1,533 shares during the last quarter. Caden Capital Partners LP raised its stake in shares of Danaher by 12.4% in the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after acquiring an additional 15,313 shares during the period. JARISLOWSKY FRASER Ltd lifted its holdings in shares of Danaher by 10.8% in the 4th quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock worth $132,524,000 after acquiring an additional 55,908 shares during the last quarter. HighPoint Advisor Group LLC purchased a new position in shares of Danaher during the 4th quarter worth approximately $2,614,000. Finally, Norden Group LLC acquired a new stake in Danaher in the 1st quarter valued at approximately $4,151,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on DHR shares. The Goldman Sachs Group raised their price target on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada increased their target price on shares of Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Evercore ISI reduced their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Jefferies Financial Group began coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 target price for the company. Finally, TD Cowen increased their price target on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $278.94.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

NYSE DHR traded up $2.29 during trading on Monday, reaching $269.31. The company’s stock had a trading volume of 4,600,100 shares, compared to its average volume of 2,803,002. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The business’s fifty day moving average price is $260.05 and its 200-day moving average price is $255.24. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market cap of $194.50 billion, a price-to-earnings ratio of 45.65, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.05 earnings per share. As a group, analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.